ZYUS Life Sciences Closes Unit Offering and Draws on Credit Line

An announcement from ZYUS Life Sciences ( (TSE:ZYUS) ) is now available.

ZYUS Life Sciences has confirmed that its previously announced non‑brokered private placement has closed with a single tranche, raising total gross proceeds of CAD$284,300 and that no further tranches, proceeds, or securities will arise from this offering. With the financing now complete at that level, the company is evaluating additional funding options as needed and has tapped its revolving credit facility to cover working capital requirements, underscoring ongoing capital needs as it advances its non‑opioid pain drug development program.

The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.

More about ZYUS Life Sciences

ZYUS Life Sciences Corporation is a clinical-stage life sciences company listed on the TSXV under the symbol ZYUS, focused on developing and commercializing novel non‑opioid pharmaceutical drug candidates for pain management. The company aims to build an intellectual property portfolio and secure regulatory approvals for its non‑opioid therapies, targeting transformational impacts for patients while enhancing shareholder value.

Average Trading Volume: 7,713

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$44.84M

For detailed information about ZYUS stock, go to TipRanks’ Stock Analysis page.